A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer - Trial NCT05839600
Access comprehensive clinical trial information for NCT05839600 through Pure Global AI's free database. This Phase 1 trial is sponsored by Boehringer Ingelheim and is currently Recruiting. The study focuses on Solid Tumors. Target enrollment is 27 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Boehringer Ingelheim
Timeline & Enrollment
Phase 1
May 25, 2023
Nov 22, 2025
Primary Outcome
Occurrence of Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) evaluation period
Summary
This study is open to adults with advanced solid tumours. People with solid tumours for whom
 previous treatment was not successful or no treatment exists can take part.
 
 The purpose of this study is to find the highest dose of a medicine called BI 1821736 that
 people with advanced solid tumours can tolerate. BI 1821736 is a type of immunotherapy. It is
 a special virus that kills cancer cells and helps the immune system fight cancer. In this
 study, BI 1821736 is given to humans for the first time.
 
 Participants receive BI 1821736 as an infusion into a vein about every 3 weeks for up to 3
 months. Study doctors regularly check the participants' health and monitor the tumours. The
 doctors also take note of any unwanted effects that could have been caused by BI 1821736.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05839600
Non-Device Trial